• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Immunotherapy : Episode 11

Epsiode 11 - The Impact of Combination Therapies on Resource Allocations


Because combination therapy options are typically used to treat cancer, managed care professionals explore the high costs of newer treatment options for the treatment of cancer and raise questions about how the costs of drugs are determined. The discussion leads into a debate about whether high costs of combination therapies will underestimate their benefits and deter patients from receiving such necessary therapy.

Daniel J. George, MD, explains that different combination regimens have different dosage requirements. Combinations with ipilimumab require a different dosage regimen than immunotherapy, which impacts decisions on how to allocate financial resources.

Dr George continues by explaining that when looking at the cost-benefit ratio for a combination therapy, the cost should be determined based on the life span of the patient and should include all subsequent therapies.

Jeffrey Weber, MD, PhD, questions whether combination therapies currently in developmental stages, such as PD1 and Ipi, will be affordable to patients due to their high costs.

Because there is no clear answer to whether or not a patient will be able to afford a therapy option, Michael Kolodziej, MD, concludes that oncologists will need to base treatment decisions on the overall value of a treatment’s benefits. If a patient will be treated with a combination therapy, the treatment should be used in a setting where the patient has the potential for long-term survival.

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Yael Mauer, MD, MPH
Related Content
© 2024 MJH Life Sciences
All rights reserved.